-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medulloblastoma (medulloblastoma) is a highly malignant glioma that occurs mainly in the back of the skull of children under 14 years of age.
myeloma recurrence is a major cause of cancer-related death in children.
study aims to investigate the clinical prognosis of relapsed myeloma and compare the molecular characteristics of diagnostic tumors and relapsed tumors that match patients.
study conducted clinical prognostic analysis of children and infants who experienced a recurrence of myeloma recruited in the SJMB03 (NCT0008520202) and SJYC07 (NCT00602667) trials, including the anatomy and time patterns of recurrence and survival after recurrence.
72 (22%) of the 329 children in the SJMB03 trial and 52 (66%) of the 79 children in the SJYC07 trial experienced recurrence, mainly in the third group and wingless tumor patterns.
although the majority of patients are distant lesions (79%), 38% of sonic hedgehog (SHH) myelomas are isolated local relapses.
recurrence time and survival rate after recurrence varies from molecular subgroup to molecular subgroup, with the incubation period of patients with group 4 tumors being longer.
therapy was associated with long survival after recurrence in patients who had not previously been treated in the SJYC07 trial.
survival rate after recurrence was 9 (7%) of the 127 patients with matching tumor pairs, followed by non-myeloma central nervous system malignancies.
group (96%) and subtype (80%) of other patients remained basically stable.
subgroup differences were observed between tumors in groups 3 and 4, consistent with genetic variants associated with MYC, MYCN, and FBXW7.
, the clinical behavior of relapsed myeloma must be studied in situational studies according to pre-treatment and molecular classification.
efficacy of radiation therapy after recurrence depends on the age of the patient and whether radiotherapy has been used in the past.
degree and pattern of molecular conservatism at the time of recurrence varies from group to group.
relapsed therapeutic tissue can be used to validate molecular targets and screen for hidden secondary malignancies.
